C12ORF57

C12ORF57 encodes a small (~126 amino acid), ubiquitously expressed, evolutionarily conserved protein with no significant paralogs that is required for corpus callosum development and ocular morphogenesis in humans (PMID:23453666). Biallelic loss-of-function mutations — including truncating changes at the initiator methionine and compound heterozygous missense/loss-of-function alleles — cause an autosomal-recessive syndrome comprising corpus callosum hypoplasia or agenesis, colobomatous microphthalmia/chorioretinal coloboma, intellectual disability, and intractable seizures across multiple independent families (PMID:23453665, PMID:23453666, PMID:24798461). Consistent with this developmental role, the gene is expressed in mouse brain and eye tissue (PMID:23453665). No enzymatic activity, binding partners, subcellular localization, or molecular pathway placement has been established in the available corpus.

1. 2013 Medium

   Establishing whether C12orf57 has any role in human development, this work tied biallelic mutations to a defined syndrome, implicating the gene in eye and brain morphogenesis.

   Evidence Autozygome analysis and exome sequencing in disease families with mouse tissue expression analysis

   PMID:23453665

   Open questions at the time

   • No biochemical function or molecular pathway identified
   • Causality demonstrated genetically but not by rescue or animal model
   • Protein localization unknown
2. 2013 Medium

   Replication across four independent consanguineous families with initiator-methionine loss-of-function mutations confirmed that C12orf57 is specifically required for corpus callosum development and characterized the protein as a conserved 126-aa product with no paralogs.

   Evidence Whole-exome sequencing, Sanger confirmation, and expression analysis in multiple families

   PMID:23453666

   Open questions at the time

   • No in vitro or biochemical mechanistic data
   • Single (genetic) method
   • No structural or functional domain assignment
3. 2014 Medium

   An independent non-consanguineous family with compound heterozygous loss-of-function alleles extended the phenotypic spectrum, confirming requirement for both brain commissure and ocular development.

   Evidence Exome sequencing, Sanger validation, and clinical phenotyping of two affected siblings

   PMID:24798461

   Open questions at the time

   • Mechanism linking loss-of-function to phenotype unresolved
   • No interacting partners or substrates defined
   • No cellular assay of mutant protein

• The biochemical activity, subcellular localization, binding partners, and molecular pathway through which C12ORF57 controls corpus callosum and eye development remain entirely undefined.
• No enzymatic or molecular activity assigned
• No physical interactors identified
• No pathway placement